Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories

Rosetta Genomics Ltd. has announced that it has successfully completed the acquisition of Parkway Clinical Laboratories Inc. (Parkway), a privately-held company owning a CLIA-certified lab located in Bensalem, Pennsylvania, for an aggregate purchase price of $2,900,000, consisting of $1,900,000 in cash and $1,000,000 of Rosetta's ordinary shares.

An additional $300,000 will be payable upon the achievement of certain milestones. The lab owned by Parkway is a CLIA-certified clinical reference laboratory with an expected $2.7M in revenues and break-even operating income in 2008.

The acquisition is expected to allow Rosetta Genomics to expedite development and validation of its microRNA-based diagnostic tests both in the U.S. and worldwide.

In addition, ownership of the CLIA-certified lab will allow Rosetta Genomics to control the commercialization of its diagnostics, including marketing, sales, and reimbursement strategy.

As previously disclosed, the first three of Rosetta Genomics' microRNA-based tests expected to enter development and validation at Parkway's facilities this year:

• Differentiating squamous from non-squamous non-small cell lung cancer- This test is designed to differentiate squamous from non-squamous non-small cell lung cancer (NSCLC) using a single microRNA. The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Certain angiogenesis inhibitors for non-squamous NSCLC include a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC. In addition, several other targeted drugs for NSCLC currently under development may require this sensitive differentiation.

• Differentiating mesothelioma from adenocarcinoma - This differentiation is critical for optimal therapy, but is often difficult to perform. Currently, there is no objective, standardized test to aid pathologists in differentiating between the many possible tumors in the lung and pleura. Based on several microRNA biomarkers, this test is designed to separate mesothelioma from adenocarcinoma tumors including lung adenocarcinoma and metastases to the lung or to the pleura.

• Identifying origin of metastases (CUP) - In 3%-5% of all new cancer patients, clinicians cannot identify the origin of a patients' tumor. This information is crucial for determining treatment type. As demonstrated in a paper published by Rosetta Genomics and collaborators in the April issue of Nature Biotechnology, Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancer types. This test is designed to assist clinicians to accurately identify the origin of tumors.

In addition, the company expects the following three tests to enter development during 2009-2010: response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer.